Last update 08 May 2025

Bevacizumab biosimilar (Celltrion)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab biosimilar
+ [2]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Carcinoma to the Uterine Cervix
Norway
17 Aug 2022
Metastatic Carcinoma to the Uterine Cervix
Liechtenstein
17 Aug 2022
Metastatic Carcinoma to the Uterine Cervix
Iceland
17 Aug 2022
Metastatic Carcinoma to the Uterine Cervix
European Union
17 Aug 2022
Platinum-Sensitive Fallopian Tube Carcinoma
Liechtenstein
17 Aug 2022
Platinum-Sensitive Fallopian Tube Carcinoma
Iceland
17 Aug 2022
Platinum-Sensitive Fallopian Tube Carcinoma
Norway
17 Aug 2022
Platinum-Sensitive Fallopian Tube Carcinoma
European Union
17 Aug 2022
Platinum-Sensitive Primary Peritoneal Carcinoma
Liechtenstein
17 Aug 2022
Platinum-Sensitive Primary Peritoneal Carcinoma
Norway
17 Aug 2022
Platinum-Sensitive Primary Peritoneal Carcinoma
European Union
17 Aug 2022
Platinum-Sensitive Primary Peritoneal Carcinoma
Iceland
17 Aug 2022
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
Liechtenstein
17 Aug 2022
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
Iceland
17 Aug 2022
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
Norway
17 Aug 2022
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
European Union
17 Aug 2022
Renal Cell Carcinoma
Norway
17 Aug 2022
Renal Cell Carcinoma
Liechtenstein
17 Aug 2022
Renal Cell Carcinoma
Iceland
17 Aug 2022
Renal Cell Carcinoma
European Union
17 Aug 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of LungPhase 3
United States
01 Feb 2019
Non-squamous non-small cell lung cancerPhase 3
United States
01 Feb 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
689
(CT-P16)
obpvijolxw(igmomaphko) = npwycjtrnt oemomcrltz (inbkyyfzjd, qlwsdhwagg - fleqslfelf)
-
17 Mar 2025
(Avastin)
obpvijolxw(igmomaphko) = hqvotoevrp oemomcrltz (inbkyyfzjd, udefmylfyb - blmnutrdrq)
Phase 3
689
(qjfmmnjxpq) = hztwtqiyif dbsagpqmgo (sdhthsqxic, 40.34 - 50.89)
Similar
07 Dec 2024
(qjfmmnjxpq) = nddvbuwbzc dbsagpqmgo (sdhthsqxic, 40.86 - 51.35)
Phase 3
689
Paclitaxel+Carboplatin+Bevacizumab-CT-P16
(krgntpavgm) = axtiyimswf uorokzzphz (clvazsfwmb, 37.16 - 47.64)
Similar
28 Sep 2022
Paclitaxel+Carboplatin+Bevacizumab
(krgntpavgm) = tufnmzcocu uorokzzphz (clvazsfwmb, 36.88 - 47.27)
Phase 3
689
qnmmxdwsal(jbciwmujpb) = The safety profile including the incidence of positive ADA results of CT-P16 up to 1 year from enrollment of the last patient was similar to that of BV. lkgttfzgku (hbkeqmdaxz )
Positive
10 Sep 2022
Phase 1
-
141
(CT-P16)
(jgozmhdzqh) = igietxcbys qzlyyqbuoo (rzdkvmgyvj, xhpmnclzka - iqilcfqxjo)
-
25 Jul 2019
(EU-approved Avastin)
(jgozmhdzqh) = wdvefgifup qzlyyqbuoo (rzdkvmgyvj, dgcynzouki - jiupngekhz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free